Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antienterococcal antibiotics.

A Lefort1, J L Mainardi, M Tod

  • 1Service de Médecine Interne, Hôpital Beaujon, Clichy, France.

The Medical Clinics of North America
|January 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The environmental impacts and costs of cefotaxime versus ceftriaxone: An example drawn from Paris hospitals.

Infectious diseases now·2026
Same author

Temocillin efficacy and emergence of resistance in Enterobacter cloacae Complex in a murine peritonitis model.

The Journal of antimicrobial chemotherapy·2026
Same author

Ceftriaxone versus cefotaxime: a scoping review of resistance selection, Clostridioides difficile risk, economic implications and environmental impacts.

Infectious diseases now·2026
Same author

Compassionate Use of Olorofim for Invasive Mold Infections: A Nationwide Observational Study in France.

Open forum infectious diseases·2026
Same author

Imported loiasis: Diagnostic and therapeutic challenges.

Infectious diseases now·2025
Same author

[Short antibiotic therapy in hospitalized pneumonia: A cohort study].

La Revue de medecine interne·2024
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Treating severe enterococcal infections is challenging due to resistance. Microbiology lab testing and new drug development are crucial for better treatment strategies and improved patient outcomes in these life-threatening infections.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Severe enterococcal infections pose significant treatment challenges with current antibacterial agents.
  • Acquired resistance mechanisms in enterococci complicate therapeutic approaches.
  • These infections predominantly affect immunocompromised (deficient) hosts, increasing severity.

Purpose of the Study:

  • To highlight the difficulties in treating severe enterococcal infections.
  • To emphasize the critical role of microbiology laboratory services in guiding treatment.
  • To advocate for prospective multicenter clinical trials to refine therapeutic strategies.

Main Methods:

  • Determining Minimum Inhibitory Concentrations (MICs) and Minimum Bactericidal Concentrations (MBCs).

Related Experiment Videos

  • Identifying effective synergistic antimicrobial combinations through laboratory testing.
  • Reviewing the current landscape of clinical development for new antibacterial compounds.

    • Main Results:

    • Current antibacterial agents present difficulties in treating severe enterococcal infections.
    • Microbiology laboratory data (MICs, MBCs, synergy testing) are essential for effective treatment.
    • New compound development shows promise for addressing resistant enterococcal infections.

    Conclusions:

    • Effective management of severe enterococcal infections requires a combination of laboratory support and strategic therapeutic approaches.
    • Prospective clinical trials are needed to establish optimal treatment guidelines.
    • Promising new antibacterial agents are under development for these difficult-to-treat infections.